Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Account Payables: 2020-2025

Historic Change in Account Payables for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $2.0 million.

  • Xeris Biopharma Holdings' Change in Account Payables rose 20.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year increase of 24.96%. This contributed to the annual value of -$9.6 million for FY2024, which is 238.14% down from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Change in Account Payables is $2.0 million, which was up 145.07% from -$4.4 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Change in Account Payables high stood at $6.9 million for Q1 2023, and its period low was -$5.2 million during Q4 2024.
  • Over the past 3 years, Xeris Biopharma Holdings' median Change in Account Payables value was $80,000 (recorded in 2023), while the average stood at -$93,182.
  • Data for Xeris Biopharma Holdings' Change in Account Payables shows a peak YoY increase of 456.57% (in 2024) and a maximum YoY decrease of 2,090.00% (in 2024) over the last 5 years.
  • Over the past 5 years, Xeris Biopharma Holdings' Change in Account Payables (Quarterly) stood at $4.4 million in 2021, then plummeted by 84.15% to $690,000 in 2022, then plummeted by 151.16% to -$353,000 in 2023, then crashed by 1,373.94% to -$5.2 million in 2024, then rose by 20.75% to $2.0 million in 2025.
  • Its Change in Account Payables was $2.0 million in Q3 2025, compared to -$4.4 million in Q2 2025 and $4.1 million in Q1 2025.